[1] | Kim MA, Oh JK, Kim BW, Chay D, Park DC, Kim SM, Kang ES, Kim JH, Cho CH, Shin HR and Seo K. Prevalence and Seroprevalence of Low-Risk Human Papillomavirus in Korean Women. Journal of Korean Medical Sciences, 2012; 27(8): 922–928. |
[2] | Aminu M, Gwafan JZ, Inabo HI, Oguntayo AO, Ella EE, and Koledade AK. Seroprevalence of human papillomavirus immunoglobulin G antibodies among women presenting at the reproductive health clinic of a university teaching hospital in Nigeria. International Journal of Womens Health, 2014; 6: 479–487. |
[3] | Castro FA, Dominguez A, Puschel K, Van De Wyngard V, Snijders PJF, Franceschi S, Pawlita M, Ferreccio C. Serological prevalence and persistence of high-risk human papillomavirus infection among women in Santiago, Chile. BMC Infectious Diseases, 2014; 14: (361): 1-8. |
[4] | Bernard, H.U., Burk, R.D., Chen, Z., van Doorslaer, K., Hausen, H. and de Villiers, E.M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology, 2010; 401:70-79. |
[5] | Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine, 2006; 24(Suppl 3):S3/35–S3/41. |
[6] | Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monogr., 2003:3–13. |
[7] | de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infectious Diseases, 2007; 7:453-459. |
[8] | Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, Liaw KL, Nygård J, Nygård M. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. Journal of Infectious Diseases, 2007; 196: 1447-1454. |
[9] | Smith S, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: a global review. Journal of Adolescence Health, 2008; 43: S5-25, S25.e1-41. |
[10] | Palmroth J, Namujju P, Simen-Kapeu A, Kataja V, Surcel HM, Tuppurainen M, Yliskoski M, Syrjänen K, Lehtinen M. Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes. Scand. Journal of Infectious Diseases, 2010; 42:379-384. |
[11] | Namujju PB, Surcel HM, Kirnbauer R, Kaasila M, Banura C, Byaruhanga R, Muwanga M, Mbidde EK, Koskela P, Lehtinen M. Risk of being seropositive for multiple human papillomavirus types among Finnish and Ugandan women. Scand Journal of Infectious Diseases, 2010; 42: 522-526. |
[12] | Namujju PB, Hedman L, Hedman K, Banura C, Mbidde EK, Kizito D, Byaruhanga RN, Muwanga M, Kirnbauer R, Surcel HM, Lehtinen M. Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence. BMC Research Notes, 2011a; 6(4):170. |
[13] | Namujju PB, Waterboer T, Banura C, Muwonge R, Mbidde EK, Byaruhanga R, Muwanga M, Surcel HM, Pawlita M, Lehtinen M. Risk of seropositivitay to multiple oncogenic human papillomavirus (HPV) types among HIV positive and HIV negative Ugandan women. Journal of General Virology, 2011b; 92: 2776-2783. |
[14] | Namujju PB. Occurrence of infections with multiple human papillomavirus (HPV) types among Finnish and Ugandan women. National Institute for Health and Welfare (THL). Research 80, 2012. 141pages. Helsinki, Finland. |
[15] | Barnabas, R.V., Laukkanen, P., Koskela, P., Kontula, O., Lehtinen, M. and Garnett, G.P. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Medicine, 2006; 3:e138. |
[16] | Syrjänen S, Waterboer T, Sarkola M, Michael K, Rintala M, Syrjänen K, Grenman S, Pawlita M. Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy. Journal of General Virology, 2009a; 90: 1515-1526. |
[17] | Syrjänen K, Shabalova I, Naud P, Kozachenko V, Derchain S, Zakharchenko S, Roteli-Martins C, Nerovjna R, Longatto-Filho A, Kljukina L, Tatti S, Branovskaja M, Hammes LS, Branca M, Grunjberga V, Erzen M, Sarian LO, Juschenko A, Costa S, Podistov J, Syrjänen, S. New Independent States of the Former Soviet Union and the Latin American Screening Study Research Groups. Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the New Independent States of the Former Soviet Union and the Latin American Screening study cohorts. International Journal of Gynecology and Cancer, 2009b; 19:934-942. |
[18] | Dahlstrom LA, Tran TN, Lundholm C, Young C, Sundström K, Sparén P. Attitudes to HPV vaccination among parents of children aged 12–15 years – a population-based survey in Sweden. Int J Cancer., 2010; 126:500–507. |
[19] | Ezenwa BN, Balogun MR, Okafor IP. Mothers’ human papilloma virus knowledge and willingness to vaccinate their adolescent daughters in Lagos, Nigeria. Int J Womens Health. 2013; 5:371–377. |
[20] | Bruni L, Barrionuevo-Rosas L, Serrano B, Valencia S, Brotons M, Mena M, Cosano R, Muñoz J, Bosch FX, de Sanjosé S, Castellsagué X. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Nigeria. Summary Report. Mar 17, 2014 [Accessed 2016-09-27]. |
[21] | Okolo C, Franceschi S, Adewole I, Thomas JO, Follen M, Snijders PJ, Meijer CJ, Clifford GM. Human papillomavirus infection in women with and without cervical cancer in Ibadan, Nigeria. Infectious Agent Cancer, 2010; 5(1):24. |
[22] | Nnodu O, Erinosho L, Jamda M, Olaniyi O, Adelaiye R, Lawson L, Odedina F, Shuaibu F, Odumuh T, Isu N, Imam H, Owolabi O, Yaqub N, Andrew Zamani A. Knowledge and attitudes towards cervical cancer and human papillomavirus: a Nigerian pilot study. African Journal of Reproductive Health, 2010; 14:95–108. |
[23] | Markowitz L, Dunne EF, Saraiya M, Lawson H, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on immunization practices. Mortality and Morbidity Weekly Reports (MMWR), 2007; 56:1–24. |
[24] | Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04- adjuvanted vaccines against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet, 2009; 374:301-314. |
[25] | Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G, for the HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncology, 2012; 13(1):89-99. |
[26] | World Health Organization: Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 – conclusions and recommendations. Wkly Epidemiol Rec 2014, 89: 221-236. |
[27] | Hamsikova E, Ludvikova V, Stasikova J, Tachezy R. Cross-sectional study on the prevalence of HPV antibodies in the general population of the Czech Republic. Sex Transm Infect 2013; 89: 133-137. |
[28] | Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. New England Journal of Medicine, 1998; 338(7): 423-428. |
[29] | Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, Bratti MC, Sherman ME, Rodriguez AC, Castle PE, Morales J, Alfaro M, Wright T, Chen S, Clayman B, Burk RD, Viscidi RP: Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 2003, 89(7):1248-1254. |
[30] | Viscidi RP, Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC, Rodriguez AC, Sherman ME, Wang S, Clayman B, Burk RD: Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev., 2004, 13(2): 324-327. |
[31] | Ho GY, Studentsov YY, Bierman R, Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiology Biomarkers Prev 2004, 13(1):110-116. |
[32] | Clifford GM, Shin HR, Oh JK, Waterboer T, Ju YH, Vaccarella S, Quint W, Pawlita M, Franceschi S. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev, 2007; 16(9):1874-1879. |
[33] | Robbins HA, Li Y, Porras C, Pawlita M, Ghosh A, Rodriguez AC, Schiffman M, Wacholder S, Kemp TJ, Gonzalez P, Schiller J, Lowy D, Esser M, Matys K, Quint W, van Doorn LJ, Herrero R, Pinto LA, Hildesheim A, Waterboer T, Safaeian M: Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. BMC Infectious Diseases, 2014; 14:120. |
[34] | Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, Rose RC. (2001) Immunological analyses of human papillomavirus capsids. Vaccine. Vol. 19:1783-93. |
[35] | Koutsky, L.A., Ault, K.A., Wheeler, C.M., Brown, D.R., Barr, E., Alvarez, F.B., Chiacchierini, L.M. and Jansen, K.U. (2002). Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:1645-51. |
[36] | Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, Rose RC. (2001) Immunological analyses of human papillomavirus capsids. Vaccine. Vol. 19:1783-93. |
[37] | Skiba D, Mehlhorn G, Fasching PA, Beckmann MW, Ackermann S. Prognostic significance of serum antibodies to HPV-16 L1 virus-like particles in patients with invasive cervical cancer. Anticancer Research, 2006; 26:4921-4926. |
[38] | Adekunle A, Sule WF, Oluwayelu, DO. High negativity of IgG antibodies against human papillomavirus type 6, 11, 16 and 18 virus-like particles in healthy women of childbearing age. Journal of Experimental and Integrated Medicine, 2014; 4(1):37-41. |
[39] | Lehtinen M, Kaasila M, Pasanen K, Patama T, Palmroth J, Laukkanen P, Pukkala E, Koskela P. Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. International Journal of Cancer, 2006; 119:2612-2619. |
[40] | Kaasila M, Koskela P, Kirnbauer R, Pukkala E, Surcel HM, Lehtinen M. Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women. International Journal of Cancer, 2009; 125:2166-172. |
[41] | Okonko IO, Ofoedu V, Okerentugba PO, Frank-Peterside N. Seroepidemiology and high negativity of IgG antibodies against human papillomavirus (HPV) type 6, 11, 16 and 18 virus-like particles in women of childbearing age in Port Harcourt, Nigeria. Journal of Immunoassay and Immunochemistry, 2015; 36(02): 210-220. |
[42] | Moscicki AB. Impact of HPV infection in adolescent populations. J Adolesc Health. 2005; 37:S3–S9. |
[43] | Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, Ning L, Killeen J, Kamemoto L, Hernandez BY. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Research, 2008; 68:8813–8824. |
[44] | Castle PE, Shields T, Kirnbauer R, Manos MM, Burk RD, Glass AG, Scott DR, Sherman ME, Schiffman M: Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. Sex Transm Dis. 2002, 29: 182-187. |
[45] | Marais DJ, Sampson C, Jeftha A, Dhaya D, Passmore JS, Denny L, Rybicki EP, Van Der Walt E, Stephen LXG and Williamson A. More men than women make mucosal IgA antibodies to Human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population. BMC Infectious Diseases, 2006; 6:95. |
[46] | Ogoina D, Musa BO, Onyemelukwe GC. Human papilloma virus (HPV) infection is associated with HIV-1 infection and AIDS in HIV-infected adult patients from Zaria, Northern Nigeria. Pan African Medical Journal, 2013; 15:38. |
[47] | Gravitt, P.E., Kamath, A.M., Gaffikin, L., Chirenje, Z.M., Womack, S. and Shah, K.V. Human papillomavirus genotype prevalence in high-grade squamous intraepithelial lesions and colposcopically normal women from Zimbabwe. Int. J. Cancer, 2002; 100: 729–732. |
[48] | Xi LF, Toure P, Critchlow CW, Hawes SE, Dembele B, Sow PS, Kiviat NB. Prevalence of specific types of human papillomavirus and cervical squamous intraepithelial lesions in consecutive, previously unscreened, West-African women over 35 years of age. International Journal Cancer, 2003; 103: 803–809. |
[49] | De Vuyst H, Steyaert S, Van Renterghem L, Claeys P, Muchiri L, Sitati S, Vansteelandt S, Quint W, Kleter B, Van Marck E, Temmerman M. Distribution of human papillomavirus in a family planning population in Nairobi, Kenya. Sexual Transmitted Diseases, 2003; 30: 137–142. |
[50] | Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, Oladepo O, Smith JS, Arslan A, Munoz N, Snijders PJF, Meijer CJLM and Franceschi S. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. British Journal of Cancer, 2004; 90: 638 – 645. |
[51] | World Health Organization (WHO). (2007). Human papillomavirus and HPV vaccines: technical information for policy-makers and health professionals. WHO Press, Geneva, 2007. |
[52] | Hariri S, Dunne EF, Sternberg M, Unger ER, Meadows KS, Karem KL, Markowitz LE. Seroepidemiology of human papillomavirus type 11 in the United States: results from the third National Health and Nutrition Examination Survey, 1991--1994. Sexually Transmitted Diseases, 2008; 35: 298–303. |
[53] | Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. Journal of Infectious Diseases, 2009; 200:1059–1067. |
[54] | Kim MA, Oh JK, Chay DB, Park DC, Kim SM, Kang ES, Kim JH, Cho CH, Shin HR, Seo K. Prevalence and seroprevalence of high-risk human papillomavirus infection. Obstet Gynecol. 2010; 116(4):932-940. |
[55] | Vaccarella S, Franceschi S, Snijders PJ, Herrero R, Meijer CJ, Plummer M. IARC HPV Prevalence Surveys Study Group. Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiology Biomarkers Prev., 2010; 19:503-510. |
[56] | Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Eklund C, Reilly M, Hutchinson M, Wacholder S, Harford J, Soliman AS, Burk RD, Schiffman M. The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: Implications for screen-and-treat strategies. International Journal of Cancer, 2012; 130:2111-2117. |
[57] | Louvanto K, Rintala MA, Syrjänen KJ, Grénman SE, Syrjänen SM. Incident cervical infections with high- and low-risk human papillomavirus (HPV) infections among mothers in the prospective Finnish Family HPV Study. BMC Infectious Diseases, 2011a; 11:179. |
[58] | Sarkola ME, Grénman SE, Rintala MA, Syrjanen KJ, Syrjanen SM. Effect of second pregnancy on maternal carriage and outcome of high-risk human papillomavirus (HPV). Experience from the prospective Finnish family HPV study. Gynecology and Obstetrics Investigations, 2009; 67(3): 208-216. |
[59] | Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J, Kiviat N, Galloway DA. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J. Infect. Dis., 174 (1996), pp. 927–936. |
[60] | Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis., 181 (2000), pp. 1911–1919. |
[61] | Onda T, Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. Characterization of IgA response among women with incident HPV 16 infection. Virology, 312(1): 213-221. |
[62] | Mestecky J, Fultz PN. Mucosal immune system of the human genital tract. J. Infect. Dis., 179 (Suppl. 3) (1999), pp. S470–S474. |
[63] | Heim K, Christensen ND, Hoepfl R, Wartusch B, Pinzger G, Zeimet A, Baumgartner P, Kreider JW, Dapunt O. Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different gynecologic patient groups. J. Infect. Dis., 172 (1995), pp. 395–402. |
[64] | Wang Z, Hansson BG, Forslund O, Dillner L, Sapp M, Schiller JT, Bjerre B, Dillner J. Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA. J. Clin. Microbiol., 34 (1996), pp. 3056–3062. |
[65] | Sasagawa T, Yamazaki H, Dong YZ, Satake S, Tateno M, Inoue M. Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions. Int. J. Cancer, 75 (1998), pp. 529–535. |
[66] | van Doornum G, Prins M, Andersson-Ellstrom A, Dillner J. Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection. Sex. Transm. Infect., 74 (1998), pp. 354–360. |
[67] | Petter A, Heim K, Guger M, Ciresa-Ko NA, Christensen N, Sarcletti M, Wieland U, Pfister H, Zangerle R, Hopfl R. Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women. J. Gen. Virol., 81(3) (2000), pp. 701–708. |